Wang Na, Hua Jing, Fu Yuhua, An Jun, Chen Xiangyu, Wang Chuancui, Zheng Yanghong, Wang Feilong, Ji Yingqun, Li Qiang
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital Affiliated by Tongji University, Shanghai, China.
Department of Pulmonary and Critical Care Medicine, Central Hospital of Jiading District, Shanghai, China.
Front Cell Dev Biol. 2023 Feb 27;11:1125723. doi: 10.3389/fcell.2023.1125723. eCollection 2023.
Pulmonary hypertension (PH) is a group of syndromes characterized by irreversible vascular remodeling and persistent elevation of pulmonary vascular resistance and pressure, leading to ultimately right heart failure and even death. Current therapeutic strategies mainly focus on symptoms alleviation by stimulating pulmonary vessel dilation. Unfortunately, the mechanism and interventional management of vascular remodeling are still yet unrevealed. Hypoxia plays a central role in the pathogenesis of PH and numerous studies have shown the relationship between PH and hypoxia-inducible factors family. EPAS1, known as hypoxia-inducible factor-2 alpha (HIF-2α), functions as a transcription factor participating in various cellular pathways. However, the detailed mechanism of EPAS1 has not been fully and systematically described. This article exhibited a comprehensive summary of EPAS1 including the molecular structure, biological function and regulatory network in PH and other relevant cardiovascular diseases, and furthermore, provided theoretical reference for the potential novel target for future PH intervention.
肺动脉高压(PH)是一组以不可逆的血管重塑、肺血管阻力和压力持续升高为特征的综合征,最终导致右心衰竭甚至死亡。目前的治疗策略主要集中在通过刺激肺血管扩张来缓解症状。不幸的是,血管重塑的机制和干预管理仍未明确。缺氧在PH的发病机制中起核心作用,大量研究表明PH与缺氧诱导因子家族之间的关系。EPAS1,即缺氧诱导因子-2α(HIF-2α),作为一种转录因子参与各种细胞途径。然而,EPAS1的详细机制尚未得到充分和系统的描述。本文全面总结了EPAS1,包括其在PH和其他相关心血管疾病中的分子结构、生物学功能和调控网络,此外,还为未来PH干预的潜在新靶点提供了理论参考。